Drug delivery device with a single mounting point

The drug delivery device addresses stability and absorption challenges by rotating and attaching to the gastrointestinal tract mucosa, ensuring effective oral delivery of low-permeability substances.

JP2026182889APending Publication Date: 2026-11-19BIOGRAIL APS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026194115
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-28
Filing Date
2026-08-26
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing drug delivery devices face challenges in delivering active pharmaceutical substances with low permeability and low water solubility via oral administration due to stability issues during manufacture, storage, and limited absorption in the gastrointestinal tract, primarily hindered by the gastrointestinal wall's barriers.

Method used

A drug delivery device with a central axis, comprising a first and second body portion, a single mounting portion, and an actuator mechanism that rotates relative to the second body portion, allowing attachment to the gastrointestinal tract mucosa to enhance stability and absorption.

Benefits of technology

The device ensures stability and effective absorption of low-permeability active drug substances in the gastrointestinal tract, providing secure attachment to the stomach or intestinal wall while reducing complexity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026182889000001_ABST
    Figure 2026182889000001_ABST
Patent Text Reader

Abstract

To provide a drug delivery device with an improved single mounting section. [Solution] The drug delivery device has a central axis and comprises a first body portion, a second body portion, a mounting portion, and an actuator mechanism configured to rotate the first body portion relative to the second body portion around the main axis of the drug delivery device, in which case the drug delivery device comprises only a single mounting portion.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present disclosure relates to a drug delivery device, particularly a drug delivery device for oral administration. The drug delivery device is advantageously configured to deliver an active pharmaceutical substance into the gastrointestinal tract, which includes the stomach and / or the intestines such as the small intestine and / or the large intestine (colon). BACKGROUND ART

[0002] Many active pharmaceutical substances, for example those with low permeability and / or low water solubility, are currently delivered via routes such as subcutaneous, intradermal, intramuscular, rectal, vaginal or intravenous routes. Since oral administration is likely to be the most widely accepted by patients, attempts have been made to deliver active pharmaceutical substances with low permeability and / or low water solubility via a suitable oral administration route, but success has been limited, particularly due to lack of stability and limited absorption from the digestive tract.

[0003] Stability relates to both the stability of the active pharmaceutical substance during manufacture and storage of the delivery device, and the stability of the active pharmaceutical substance during passage through the gastrointestinal tract before the active pharmaceutical substance becomes absorbable.

[0004] Limited gastrointestinal absorption is caused by the fact that absorption of the active pharmaceutical substance after oral administration is hindered by the barriers of the gastrointestinal wall, for example due to low permeability of the active pharmaceutical substance caused by pre-systemic metabolism, size and / or charge, and / or due to the water solubility of the active pharmaceutical substance.

[0005] A number of studies have been proposed to address these stability and absorption challenges, however effective solutions to the challenges remain unresolved. SUMMARY OF INVENTION PROBLEMS TO BE SOLVED BY THE INVENTION

[0006] Therefore, there is an unmet need for drug delivery devices that can deliver drug substances for absorption in gastrointestinal tissue. More generally, there remains a need for drugs and methods that enable improved drug delivery when drugs are administered orally to patients. [Means for solving the problem]

[0007] A drug delivery device is disclosed. The drug delivery device has a central axis. The drug delivery device comprises a first body portion. The drug delivery device comprises a second body portion. The drug delivery device comprises a mounting portion. The mounting portion can be attached to the first body portion. The mounting portion may have a distal end. The drug delivery device comprises an actuator mechanism. The actuator mechanism may be configured to rotate the first body portion relative to the second body portion about the principal axis of the drug delivery device. The drug delivery device comprises only a single mounting portion.

[0008] The advantage of this disclosure is that the drug delivery device ensures the stability of the active drug substance during passage through the gastrointestinal tract and further promotes the effective absorption of the active drug substance from the gastrointestinal tract after oral administration.

[0009] Furthermore, an advantage of this disclosure is that the drug delivery device provides an active attachment of the drug delivery device to the abdominal wall, such as the stomach wall and / or intestinal wall.

[0010] Furthermore, this disclosure advantageously provides oral delivery of low-permeability active drug substances within or within the endogastric tissue.

[0011] Furthermore, this disclosure advantageously reduces the complexity of drug delivery devices while maintaining effective use for purposes such as the delivery of active drug substances.

[0012] The above and other features and advantages of the present invention will be readily apparent to those skilled in the art by a detailed description of the following exemplary embodiments of the invention with reference to the accompanying drawings. [Brief explanation of the drawing]

[0013] [Figure 1] Figure 1 shows an exploded view of an exemplary drug delivery device. [Figure 2A] Figure 2A shows a perspective view of an exemplary drug delivery device. [Figure 2B] Figure 2B shows a perspective view of an exemplary drug delivery device. [Figure 3] Figure 3 shows an encapsulated drug delivery device. [Figure 4] Figure 4 shows an exploded view of an exemplary drug delivery device having a rotatable mounting section. [Figure 5A] Figure 5A shows a drug delivery device. [Figure 5B] Figure 5B shows an exploded view of the drug delivery device shown in Figure 5A. [Figure 6A] Figure 6A shows different diagrams of an exemplary drug delivery device. [Figure 6B] Figure 6B shows different diagrams of an exemplary drug delivery device. [Figure 6C] Figure 6C shows different diagrams of an exemplary drug delivery device. [Modes for carrying out the invention]

[0014] Various exemplary embodiments and details are described below, with reference to the drawings where applicable. It should be noted that the drawings may or may not be drawn to scale, and that elements of similar structure or function are represented by the same reference numerals throughout the drawings. It should also be noted that the drawings are intended solely to facilitate the description of embodiments and functions associated with those embodiments. The drawings are not intended to be a comprehensive description of the invention, or to limit the scope or physical appearance of the invention. Furthermore, illustrated embodiments do not necessarily have to have all the forms or advantages shown. Forms or advantages described in relation to a particular embodiment are not necessarily limited to that embodiment and can be implemented in any other embodiment, even if not illustrated or explicitly described in that way.

[0015] A drug delivery device having a center is disclosed. The drug delivery device comprises a first body portion. The drug delivery device comprises a second body portion. The drug delivery device comprises a mounting portion. The mounting portion is attachable to the first body portion. The mounting portion has a distal end. The drug delivery device comprises an actuator mechanism. The actuator mechanism can be configured to rotate the first body portion relative to the second body portion around the principal axis of the drug delivery device. The drug delivery device comprises only a single mounting portion.

[0016] The drug delivery device may have a size and geometric shape designed to accommodate pharmaceutical compositions for oral administration.

[0017] Drug delivery devices / pharmaceutical compositions may be configured to be taken into the body through the opening of the mouth. Therefore, the external dimensions of drug delivery devices / pharmaceutical compositions may be small enough for the user to swallow. Drug delivery devices may be adapted to deliver drug substances into the user's body via the digestive system; for example, a drug delivery device may travel from the user's mouth through the esophagus to the stomach. Furthermore, a drug delivery device may travel from the stomach to the intestines, and optionally further travel through the intestines and out through the rectum.

[0018] The drug delivery device can be configured to deliver a drug to any part of a user's digestive system, and in that case, in one example, the drug delivery device can be configured to deliver a drug substance into the user's stomach. In another example, the drug delivery device can be adapted to initiate drug delivery when the device passes through the user's stomach and enters the intestine. In other words, the drug delivery device can be configured to attach to the stomach wall or the intestinal wall, for example depending on the desired release position of the active drug substance.

[0019] The attachment portion (e.g., a single attachment portion, the only attachment portion) of the drug delivery device can be configured to interact with the inner layer of the inner surface of the gastrointestinal tract, so that the drug delivery device can, for example, adhere to the inner surface (mucosa) of the stomach, or alternatively to the mucosa of the intestine. The attachment portion can be configured to interact with the mucosa in the user's body for a certain period of time, for example, to fix or attach the drug delivery device. By attaching the drug delivery device, the drug delivery device enables the drug substance to be delivered to a part of the digestive system to provide the drug substance to the user's body. The attachment portion can be configured to interact with the mucosa, for example to inject the drug substance into the wall of the gastrointestinal tract.

[0020] As discussed herein, the attachment portion is regarded as the only attachment portion in the drug delivery device. Accordingly, that attachment portion is the sole attachment portion of the drug delivery device. The attachment portion is a single attachment portion. The drug delivery device can comprise one attachment portion and can comprise no other attachment portions. The drug delivery device can comprise the only attachment portion. The drug delivery device may comprise other forms, but may comprise only a single attachment portion configured to interact with tissue. The attachment portion and the single attachment portion may be used interchangeably.

[0021] Difficulties exist when using a single attachment portion drug delivery device, which have been overcome by the present disclosure. As a non-limiting example, the drug delivery device may vary inertia between portions of the drug delivery device via weight, high-friction elements, protrusions, and / or other forms or the like. Furthermore, the attachment portion may have an appropriate force to penetrate tissue with only the single attachment portion. Further, over-rotation may be limited or reduced in the drug delivery device.

[0022] The drug delivery device optionally has a central axis extending from a first end to a second end of the drug delivery device. The drug delivery device may have a length (e.g., the maximum extension from the first end to the second end along the central axis) in the range of 3 mm to 35 mm, for example in the range of 5 mm to 26 mm. The drug delivery device may be elongated.

[0023] The drug delivery device may have a width and / or height (e.g., the maximum extension along the width axis and the height axis, respectively) in the range of 1 mm to 20 mm. The height and width are the maximum extensions of the drug delivery device perpendicular to the central axis.

[0024] In one or more exemplary drug delivery devices, the dimensions of the drug delivery device, at least in an initial state or a first state before actuation of the attachment portion, may be represented by a length (maximum extension along the central axis), a width (maximum extension along the width axis perpendicular to the central axis), and a height (maximum extension along the height axis perpendicular to the central axis and the width axis). The height of the drug delivery device may be in the range of 1 mm to 15 mm. The width of the drug delivery device may be in the range of 1 mm to 15 mm.

[0025] In one or more exemplary drug delivery devices, the drug delivery device may be constructed in such a way as to ensure that the drug delivery portion delivers a payload or active pharmaceutical substance to internal tissue or an internal surface, for distributing the active pharmaceutical substance to a patient via a blood vessel.

[0026] It is advantageous that the drug delivery device can be attached to a specific location on the patient's intestinal wall to deliver the active drug substance. Of course, the delivery device can be attached to similarly deliver the active drug substance to another location. In one or more exemplary drug delivery devices, the drug delivery device, such as a spike (large nail), may penetrate the muscularis mucosa. In one or more exemplary drug delivery devices, the drug delivery device, such as a spike, may not penetrate the outer muscularis layer. In one or more exemplary drug delivery devices, the spike may be positioned in the submucosa. In one or more exemplary drug delivery devices, the spike may be positioned in the submucosa parallel to the intestinal wall.

[0027] The drug delivery device comprises a first main body portion. The first main body portion may consist of two parts, namely, a first main body portion and a first secondary body portion. The first main body portion has an outer surface. A first main recess and / or a first secondary recess may be formed on the outer surface of the first main body portion.

[0028] The drug delivery device optionally comprises a shell having a first shell portion. The outer surface of the first body portion may constitute at least a part of the first shell portion.

[0029] A drug delivery device comprises a mounting portion. The mounting portion may comprise a base portion and / or a needle, such as a spike. The mounting portion has a proximal end and a distal end. Therefore, a drug delivery device may have only one or a single base portion and a needle (e.g., a spike).

[0030] The attachment portion, such as a needle or spike, is optional and may have an attachment axis or extend along the attachment axis. The tip of the needle forms the distal end. In other words, the distal end is the tip of the needle. The base is located at or may constitute the proximal end of the attachment portion. The needle may have a length in the range of 1 mm to 15 mm, for example, in the range of 3 mm to 10 mm. This may reduce the risk of damaging internal tissue while simultaneously providing sufficient penetration into the internal tissue. The distal end of the attachment portion may have a tip configured to penetrate biological tissue. The distal end of the attachment portion may have a gripping portion formed to grasp biological tissue.

[0031] The needle may have a cross-sectional diameter in the range of 0.1 mm to 5 mm, for example, in the range of 0.5 mm to 2.0 mm.

[0032] The needle may be straight and / or curved. The needle may have a straight main portion. The needle may have a secondary portion, for example, between the main portion and the distal end, or between the base and the main portion. The secondary portion may be curved.

[0033] The needle may comprise two or more straight sections formed at an angle. For example, the needle may have a proximal section extending at a first angle from the connection point to the drug delivery device, and a distal section extending at a second angle from the connection point to the drug delivery device. The first and second angles may be different. The proximal section may be connected to the distal section at a joint (e.g., a bend, connection, or angle), and there may be a joint angle between the proximal and distal sections. The joint angle may be acute, obtuse, or right. The angle may be, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 140, 150, 160, or 170 degrees. This is advantageous because it allows for different mounting angles when the needle interacts with the internal lining. This may allow for improved attachment of drug delivery devices while helping to reduce or avoid tissue damage. Furthermore, the joint may be flexible. Alternatively, the joint may not be flexible.

[0034] The joint may be located at or near the center of the needle's length. Alternatively, the joint may be located at 40, 45, 55, 60, or 65 percent of the needle's length from the proximal end.

[0035] In one or more exemplary mounting parts, the needle may have three, four, or five different parts at different angles, each connected by a joint. In some repetitions, some or all of the different parts may be straight or curved. Each joint may or may not be flexible.

[0036] The mounting portion of the drug delivery device can be considered any type of mounting portion that can enable the drug delivery device to be attached to living tissues of a human or animal body, such as the stomach wall, internal organs, and / or intestinal wall. The mounting portion can be adapted to extend away from the central axis of the drug delivery device and / or the central axis of the mounting portion. This may mean that the mounting portion can extend radially, for example, away from the circumferential surface (radial direction) of the first and / or second main body portion, so that the mounting portion extends further radially than the circumferential or outer surface of the main body portion.

[0037] The mounting portion can be fixed to the first main body portion or rotatably mounted.

[0038] In one or more exemplary drug delivery devices, the drug delivery device comprises a second body portion. The second body portion may consist of two parts, namely a second main body portion and a second secondary body portion. A mounting portion may be fixed to or rotatably mounted to the second body portion instead of the first body portion. A second main recess and / or a second secondary recess may be formed on the outer surface of the second body portion.

[0039] Therefore, the mounting portion may be fixed to or rotatably attached to either the first body portion or the second body portion. The mounting portion may be fixed to or rotatably attached to only one of the first body portion or the second body portion. As described above, the drug delivery device has only a single mounting portion attached to either the first body portion or the second body portion. If the mounting portion is attached to the first body portion, it is not attached to the second body portion. If the mounting portion is attached to the second body portion, it is not attached to the first body portion.

[0040] In one or more exemplary drug delivery devices, the actuator mechanism is configured to rotate the first body portion relative to a second body portion around the principal axis of the drug delivery device. The principal axis may be parallel to and / or coincide with the central axis.

[0041] In one or more exemplary drug delivery devices, a first body portion is configured to rotate in a first direction, and / or a second body portion is configured to rotate in a second direction opposite to the first direction.

[0042] A drug delivery device may include a frame (structure) portion, in which case different parts, such as a first body portion and / or a second body portion, etc., may be attached to the frame portion, for example, fixed or rotatably attached. In one or more exemplary drug delivery devices, an actuator mechanism or part thereof may be attached to the frame portion. This may provide separate rotation of the first body portion and the second body portion relative to the frame portion.

[0043] A rotational connection between the first and second body portions allows the first body portion to rotate relative to the second body portion without the two parts separating from each other before the mounting portion interacts with internal tissue such as mucosa. Such a connection can be obtained in several ways; in one example, the first body portion has a plug connection and the second body portion has a socket connection, and this plug and socket configuration further allows the first body portion to rotate relative to the second body portion. A second example can provide a shaft portion that can be coaxial with the central axis and / or principal axis, in which case the first and second body portions are configured to receive the shaft portion, and stop devices are positioned at the first and second ends of the shaft portion on each side of the coupled first and second body portions to prevent the first and second body portions from sliding longitudinally along the shaft portion. The shaft portion can be integrated with the first or second body portion.

[0044] If a shaft is used, it can be made from any number of different materials. For example, the shaft can be made from metals and / or alloys and / or polymers and / or composite materials and / or combinations thereof.

[0045] The first and / or second body parts can be arranged to rotate freely relative to each other, for example, in at least the second state, thereby allowing the mounting part to rotate. For example, if the mounting part is on the first body part, the mounting part is rotatable relative to the second body part. Separately, if the mounting part is on the second body part, the mounting part is rotatable relative to the first body part.

[0046] Accordingly, the mounting portion may be adapted to contact and / or penetrate the tissue of the gastrointestinal tract. The mounting portion may be moved in such a manner that it can penetrate the mucosa in order to fix the drug delivery device in a position within the gastrointestinal tract, such as the stomach or intestine, by rotating the main body portions relative to each other using elastic force. The penetrating force may originate from an actuator mechanism / elastic portion, in which case the elastic portion may be adapted to store elastic force that can push the mounting portion toward the tissue when the elastic force of the elastic portion is released at least partially. The elastic portion may take the form of, for example, a spring or spring element, such as a torsion spring or a power spring, in which case the spring can be wound up to store mechanical energy, and the mechanical energy can be transmitted to the first and / or second main body portions. When the mechanical energy is released, the first main body portion can rotate relative to the second main body portion, and the mechanical energy can be transmitted to the mounting portion via the main body portion. The actuator mechanism may comprise an elastic portion configured to apply force to the first and / or second main body portions.

[0047] In the context of this explanation, the term “rotational force” may be understood as torque, moment, moment of force, rotational force, or “effect of rotation.” Another definition of the term “rotational force” may be the product of the magnitude of the force and the perpendicular distance of the line of action of the force from the axis of rotation. Rotational force may be considered a force transmitted from the elastic part of the drug delivery device through the main body to the mounting part.

[0048] The rotational force may be defined as being large enough to penetrate the gastrointestinal tract tissue. When the rotational force acts on both the first and second main body parts, the mounting part may be in contact with the surface to which it is to be mounted.

[0049] In one or more exemplary drug delivery devices, the drug delivery device may comprise one or more resistance configurations. These resistance configurations can be configured to vary the resistance to the movement of at least a portion of the drug delivery device. One or more resistance configurations may be located in a first body portion. One or more resistance configurations may be located in a second body portion. One or more resistance configurations may be located in both the first and second body portions. In one or more exemplary drug delivery devices, the drug delivery device may not comprise any resistance configurations. In one or more exemplary drug delivery devices, the first body portion and / or the second body portion may comprise resistance configurations.

[0050] In one or more exemplary drug delivery devices, the resistance configuration can be selected from one or more of the following: a high-friction surface; a configuration configured to change inertia; and a configuration configured to generate turbulence. The resistance configuration may comprise micro (micro-bodies) and / or micro (micro-spikes). The resistance configuration may comprise a flexible mine tube (air duct). The resistance configuration may comprise a bio-adhesion configuration. The resistance configuration may be a retaining element or retaining configuration.

[0051] For example, a drug delivery device may have a high-friction surface. This surface may have higher friction than any other surface of the drug delivery device. For example, the high-friction surface may have one or more of the following: ridges, waves, protrusions, membranes, paddles, fins, and bulges.

[0052] In one or more exemplary drug delivery devices, the resistance configuration may consist of one or more spikes. The one or more spikes can be positioned in opposite directions with respect to the mounting portion to resist the movement of the first or second body portion as it completes its rotation when reverse rotation occurs.

[0053] In one or more exemplary drug delivery devices, the resistance configuration may include weight transfer of the drug delivery device.

[0054] In one or more exemplary drug delivery devices, the mounting portion may be configured to reduce the resistance of the mounting portion. For example, the mounting portion may be a small gauge. Furthermore, the mounting portion may be perforated and / or cut. This can be used in conjunction with or instead of the resistance configuration.

[0055] In one or more exemplary drug delivery devices, the second body portion may have higher inertia than the first body portion. In one or more exemplary drug delivery devices, the first body portion may have lower inertia than the second body portion.

[0056] For example, the first body portion and / or the second body portion may have a protrusion. The protrusion may be configured to press against the mounting portion.

[0057] For example, the first body portion may have a lighter weight than the second body portion. The drug delivery device may have a weight balance section that is off-center. The first body portion and the second body portion may have different area ratios. The first body portion may have a pin connection to the second body portion. The drug delivery device may be molded and / or configured to generate turbulent motion. For example, the drug delivery device may be egg-shaped. The drug delivery device may be top-shaped.

[0058] In one or more exemplary drug delivery devices, the second main body may have a heavier weight than the first main body. In one or more exemplary drug delivery devices, the second main body may have a lighter weight than the first main body. In one or more exemplary drug delivery devices, the second main body may have a heavier or lighter weight than the first main body.

[0059] In one or more exemplary drug delivery devices, the second body portion may have a higher density than the first body portion. In one or more exemplary drug delivery devices, the second body portion may have a lower density than the first body portion.

[0060] In one or more exemplary drug delivery devices, the drug delivery device may have a higher density than human tissue. For example, the drug delivery device may have a higher density than stomach tissue. The drug delivery device may have a higher density than intestinal tissue, such as one or more of the small and large intestines.

[0061] The drug delivery device can have a higher density than the fluids held within the gastrointestinal system. This is advantageous because it allows the drug delivery device to be located at the bottom of a given organ, such as adjacent to tissue.

[0062] For example, a drug delivery device may have a higher density in the stomach than digestive secretions such as gastric acid. A drug delivery device may have a higher density than fluids and / or liquids that are retained, for example, remain in the stomach. A drug delivery device may have a density that allows it to be located at the bottom of the stomach.

[0063] For example, a drug delivery device may have a density higher than that of a fluid and / or liquid, which is retained, for example, in one or more of the intestines, such as the small and large intestines. The drug delivery device may have a density that allows the drug delivery device to be located at the bottom of one or more of the intestines, such as the small and large intestines.

[0064] In one or more exemplary drug delivery devices, the distance between the mounting axis and the main axis of the mounting portion is greater than 0.5 mm, for example, at least in the operating state or second state of the drug delivery device and optionally in the initial state of the drug delivery device.

[0065] In one or more exemplary drug delivery devices, a mounting portion is rotatably attached to a first body portion, for example, via a first joint connection having a first axis of rotation. In one or more exemplary drug delivery devices, a mounting portion is rotatably attached to a first body portion via a hinge and configured to rotate around a first axis of rotation perpendicular to or parallel to the main axis. In other words, the mounting portion is optionally configured to rotate around a first axis of rotation with respect to the first body portion, for example. The first axis of rotation may be parallel to the central axis and / or the main axis. The first axis of rotation may form a first angle with the central axis and / or the main axis. The first angle may be less than 15°. The first angle may be in the range of 75° to 105°, such as 90° ± 5° or 90°.

[0066] In one or more exemplary drug delivery devices, a first body portion may define a first body recess (e.g., a cavity, an elongated hole, or a hole) extending to the outer surface of the first body portion. The first body recess may be formed by solid walls on all sides except the open outermost surface. A mounting portion may be rotatably connected within the first body recess along the first mounting portion axis. The first mounting portion axis may be, for example, a pin (e.g., an arm, a support). The first mounting portion axis may be parallel to the central axis and / or principal axis. The first mounting portion axis may be angled with respect to the central axis and / or principal axis. Thus, the mounting portion may be configured to rotate within the recess along the first mounting portion axis. The rotation of the mounting portion may also be stopped at the end face of the recess.

[0067] The first body recess may extend along a portion of the outer surface of the first body. The first body recess may extend entirely along the outer circumference of the first body. The first body recess may extend over 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of the outer circumference of the first body. The first body recess may extend beyond 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of the outer circumference of the first body. The first body recess may extend over 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or less than 100% of the outer circumference of the first body.

[0068] The first body recess may extend from the outer surface toward the central axis over 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. The first body recess may extend from the outer surface toward the central axis over more than 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. The first body recess may extend from the outer surface toward the central axis over less than 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device.

[0069] In one or more exemplary drug delivery devices, the first body recess may extend circumferentially or partially circumferentially around a first body portion having a central axis which is longitudinal. The first body recess may extend perpendicular to the central axis and / or primary access (e.g., along a cross-section of the drug delivery device perpendicular to the central axis and / or primary access). The first body recess may have any number of shapes. For example, the first body recess may be a part of a circle, such as a semicircle. The first body recess may be a triangle. The first body recess may be a sector of a circle. The first body recess may be a curved corner connected by two straight corners. The first body recess may be two curved corners connected to each other by two straight corners.

[0070] Therefore, the mounting portion may rotate along the first mounting portion axis in order to move perpendicular to the central axis and / or principal axis. In certain embodiments, the mounting portion may rotate at an angle between perpendicular and parallel to the central axis and / or principal axis.

[0071] In one or more exemplary drug delivery devices, as the first body portion and / or the second body portion rotate relative to each other, the mounting portion rotates out of its recess (e.g., the recess of the first body portion or the recess of the second body portion) due to the rotation of the first body portion and / or the second body portion. Then, due to the continued rotation of the first body portion and / or the second body portion, the mounting portion penetrates the tissue, holding the drug delivery device in place.

[0072] In one or more exemplary drug delivery devices, the mounting portion extends, for example, in a direction away from the first body portion, at least in the operating state of the drug delivery device and optionally in the initial state of the drug delivery device. In other words, the needle may extend from the outer surface of the first body portion, for example, at least in the operating state of the drug delivery device and optionally in the initial state. To put it another way, the axis of the first mounting portion may form an angle of at least 45° with the central axis and / or principal axis, for example, at least in the operating state of the drug delivery device and optionally in the initial state of the drug delivery device. The extension of the mounting portion in a certain direction should be understood as a direction from the proximal end of the mounting portion / needle portion to the distal end of the mounting portion along the mounting axis of the mounting portion.

[0073] The mounting portion may extend in a first principal direction in a first state of the drug delivery device and in a first secondary direction in a second state of the drug delivery device. The first principal direction and the first secondary direction may form an angle of at least 30°. The first principal direction may be parallel or substantially parallel to the central axis. The first principal direction may form an angle of less than 60° with respect to the central axis. The first secondary direction may form an angle of at least 60°, for example, about 90°, with respect to the central axis. The first secondary direction may be perpendicular to the central axis.

[0074] The distal end of the mounting portion may be configured to move, or be made to move, from a first primary position in a first state of the drug delivery device to a first secondary position in a second state.

[0075] In one or more exemplary drug delivery devices, a mounting portion is rotatably attached to a second body portion, for example, via a joint connection such as a hinge having a rotation axis, instead of a first body portion. In other words, the mounting portion is optionally configured to rotate about a second rotation axis, for example, relative to the second body portion. The second rotation axis may be parallel to the central axis and / or principal axis. The second rotation axis may form a second angle with the central axis and / or principal axis. The second angle may be less than 15°. The second angle may be in the range of 75° to 105°, for example, 90° ± 5° or 90°.

[0076] In one or more exemplary drug delivery devices, a second body portion may define a second body recess (e.g., a cavity, an elongated hole, or a hole) extending to the outer surface of the second body portion. The second body recess may be formed by solid walls on all sides except the open outermost surface. A mounting portion may be rotatably connected within the second body recess along the axis of the second mounting portion. The axis of the second mounting portion may be, for example, a pin (e.g., an arm, a support). The axis of the second mounting portion may be parallel to the central axis and / or principal axis. The axis of the second mounting portion may be angled with respect to the central axis and / or principal axis. Thus, the mounting portion may be configured to rotate within the recess along the axis of the second mounting portion. The rotation of the mounting portion may also be stopped at the end face of the second body recess.

[0077] The second body recess may extend along a portion of the outer surface of the second body. The second body recess may extend entirely along the outer circumference of the second body. The second body recess may extend over 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of the outer circumference of the second body. The second body recess may extend beyond 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of the outer circumference of the second body. The second body recess may extend over 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or less than 100% of the outer circumference of the second body.

[0078] The second body recess may extend from the outer surface toward the central axis over 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. The second body recess may extend from the outer surface toward the central axis over more than 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. The second body recess may extend from the outer surface toward the central axis over less than 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device.

[0079] In one or more exemplary drug delivery devices, a second body recess having a longitudinal central axis may extend circumferentially or partially circumferentially around the second body. The second body recess may extend perpendicular to the central axis and / or primary access (e.g., along a cross-section of the drug delivery device perpendicular to the central axis and / or primary access). The second body recess may have any number of shapes. For example, the second body recess may be a part of a circle, such as a semicircle. The second body recess may be a triangle. The second body recess may be a sector of a circle. The second body recess may be a curved corner connected by two straight corners. The second body recess may be two curved corners connected to each other by two straight corners.

[0080] Therefore, the mounting portion may rotate on the second mounting portion axis in order to move perpendicular to the central axis and / or principal axis. In certain embodiments, the mounting portion may rotate at an angle between perpendicular and parallel to the central axis and / or principal axis.

[0081] In one or more exemplary drug delivery systems, a first body portion may have a first body recess, while a second body portion may not have a second body recess. In one or more exemplary drug delivery systems, a second body portion may have a second body recess, while a first body portion may not have a first body recess. Whether a body portion has a particular recess may depend on which body portion has a mounting portion. For example, if the mounting portion is on the first body portion, the first body portion may have a first body recess, while a second body portion may not have a second body recess. Separately, if the mounting portion is on the second body portion, the second body portion may have a second body recess, while a first body portion may not have a first body recess.

[0082] In one or more exemplary drug delivery devices, when the first body portion and / or the second body portion rotate relative to each other, the mounting portion rotates with the rotation of the first body portion and / or the second body portion, allowing it to exit the respective recesses of the body portion (e.g., the first body recess and the second body recess). Then, the continued rotation of the first body portion and / or the second body portion causes the mounting portion to penetrate the tissue, thereby holding the drug delivery device in place.

[0083] In one or more exemplary drug delivery devices, the mounting portion extends, for example, at least in the operating state of the drug delivery device and optionally in the initial state of the drug delivery device, optionally in a direction away from the second body portion. In other words, the needle may extend from the outer surface of the second body portion, for example, at least in the operating state of the drug delivery device and optionally in the initial state. To put it another way, the second mounting axis may form an angle of at least 45° with the central axis and / or principal axis, for example, at least in the operating state of the drug delivery device and optionally in the initial state of the drug delivery device.

[0084] The mounting portion may extend in a second principal direction in the first state of the drug delivery device, and may extend in a second secondary direction in the second state of the drug delivery device. The second principal direction and the second secondary direction may form an angle of at least 30°. The second principal direction may be parallel or substantially parallel to the central axis. The second principal direction may form an angle of less than 60° with the central axis. The second secondary direction may form an angle of at least 60°, for example, about 90°, with the central axis. The second secondary direction may be perpendicular to the central axis.

[0085] The distal end of the mounting portion may be configured to move, or be made to move, from a second primary position in a first state of the drug delivery device to a second secondary position in a second state.

[0086] The drug delivery device comprises an actuator mechanism. The actuator mechanism is configured to move the attachment portion relative to the second body portion or the first body portion, for example, during a portion of the rotation, for example, during at least a first rotation and optionally during a second rotation. In one or more exemplary drug delivery devices, the actuator mechanism is configured to move the distal end, for example, in a second state of the drug delivery device, by rotating the first body portion relative to the second body portion and / or vice versa. The actuator mechanism may be configured to rotate the first body portion relative to the second body portion around the main axis by at least 90°, for example, at least 450°, at least 810°, at least 1170°, at least 1530°, or even at least 1890°. The actuator mechanism may also be configured to rotate the first body portion relative to the second body portion in a stepwise manner around the main axis. In other words, rotating the first body part around the main axis relative to the second body part can comprise multiple rotations, comprising a first rotation and a second rotation, for example, a first rotation followed by a first rotation during which the rotation decreases or does not occur, and then a second rotation. The second rotation following the first rotation after the first period can increase the likelihood that the drug delivery device will adhere to biological tissue. The first period, or generally the period between rotations, allows the drug delivery to move to another location within the gastrointestinal tract. In other words, if the drug delivery does not adhere to biological tissue during the first rotation, further rotations increase the chances of adhesion to internal tissue. The first rotation can be at least 90°, and the second rotation can be at least 180°. Multiple rotations can comprise a third rotation, which can be at least 180°.

[0087] The actuator mechanism optionally includes an elastic part, such as a spring element, configured to apply force to a first body portion and / or a second body portion. The elastic part may include a first part, such as a first end, connected to the first body portion. The elastic part may also include a second part, such as a second end, connected to the second body portion.

[0088] In one or more exemplary drug delivery devices, the actuator mechanism optionally comprises an expanding medium, i.e., a medium that increases in volume, for example, upon contact with a liquid, to rotate parts relative to each other. In one or more exemplary drug delivery devices, the expanding medium rotates the mounting portion relative to a first body portion or the mounting portion relative to a second body portion. In one or more exemplary drug delivery devices, the expanding medium results in the rotation of the first body portion relative to a second body portion.

[0089] The actuator mechanism, such as an elastic part, may be configured to rotate the mounting portion around a first axis of rotation relative to the first main body portion.

[0090] The actuator mechanism, such as an elastic part, may be configured to rotate the mounting portion relative to the second main body portion around a second axis of rotation.

[0091] In one or more exemplary drug delivery devices, the drug delivery device comprises a first compartment, and the drug delivery device is configured to deliver an active drug substance from the first compartment to the surrounding area of ​​the drug delivery device. The first compartment may be located on a mounting portion of a first needle, etc., at a distance, for example, within 8 mm, for example, within 5 mm, etc., from a first distal end. The mounting portion of the first needle, etc., may have one or more openings that provide access (access passage) to the first compartment. In one or more exemplary drug delivery devices, the first compartment is formed as a through-hole for a first needle.

[0092] The first compartment may be located in any part of the drug delivery device, for example, in the form of a cavity within the volume of the first body portion, the second body portion, or both the first and second body portions. In addition or alternatively, the first compartment may be an interior compartment of a mounting portion, in which case the drug substance in the first compartment may be released into the living tissue by the mounting portion penetrating into the living tissue. In addition or alternatively, the first compartment may be a compartment in the form of a recess or opening or a spike or hollow spike on the outer surface of the first and / or second body portions, in which case the drug delivery device may be adapted to release the drug substance into an organ of the body through which the drug delivery device is adapted.

[0093] In one or more exemplary drug delivery devices, the first compartment may open from the internal volume of the drug delivery device toward the external portion of the drug delivery device. In one or more examples, the first compartment may be located inside the first body portion, and the first compartment may be fluidly connected to a mounting portion, so that when the distal end of the mounting portion penetrates biological tissue, the drug substance may be released from the first compartment through the mounting portion into the biological tissue. This could be, for example, a case where the mounting portion is a tubular portion, and the tubular portion has a distal end that is in fluid communication with a first compartment of the drug delivery device.

[0094] In one or more exemplary drug delivery devices, the drug delivery device comprises a second compartment, and the drug delivery device is configured to deliver an active drug substance from the second compartment to the surrounding area of ​​the drug delivery device. The second compartment may be located on a mounting portion such as a needle, at a distance, for example, within 8 mm, for example, within 5 mm, from the distal end. The mounting portion such as a needle may have one or more openings that provide access to the second compartment. In one or more exemplary drug delivery devices, the second compartment is formed as a through-hole in the needle.

[0095] In one or more exemplary drug delivery devices, the rotational forces of the first and second body parts can push the active drug substance out of the drug delivery device, for example, out of the first or second compartment. For example, the rotational kinetic force can discharge (e.g., expel, release, or push) the active drug substance out of the drug delivery device, for example, out of the first or second compartment. The kinetic force may arise from forces unrelated to rotation.

[0096] A drug delivery device may have a first compartment or a second compartment. For example, if the mounting portion is attached to the first main body portion, the drug delivery device may have a first compartment but not a second compartment. For example, if the mounting portion is attached to the second main body portion, the drug delivery device may have a second compartment but not a first compartment.

[0097] In one or more exemplary drug delivery devices, the drug delivery device has a first state, also referred to as an initial state, in which a first body portion and a second body portion are rotationally stationary relative to each other, and a second state, also referred to as an operating state, in which the first body portion and the second body portion are rotatably movable relative to each other, for example, rotatable around the main axis of the drug delivery device. In other words, the first body portion can be fixed relative to the second body portion, for example, rotation can be prevented. The first state can be, for example, an initial state or introduction state, in which the drug delivery device is adapted to be introduced into a body, and in which the first body portion and the second body portion are stationary relative to each other. In the first state, the elastic portion can have a predetermined amount of stored energy, in which case the body portion is stationary and the energy level in the elastic portion remains unchanged.

[0098] In one or more exemplary drug delivery devices, the drug delivery device may have a first state in which a first body portion and a second body portion are rotationally stationary relative to each other, and a second state in which the first body portion and the second body portion are rotationally movable relative to each other.

[0099] In one or more exemplary drug delivery devices, the drug delivery device has a first state in which an elastic portion has a constant elastic load, and a second state in which the elastic portion releases the elastic load at least partially. In other words, the elastic portion can be biased or preloaded in the first state of drug delivery, and when released, for example by releasing a locking mechanism (i.e., when the drug delivery device is in the second state), the force from the elastic portion can affect the rotation of the first body portion relative to the second body portion, i.e., the movement of the first distal end toward the second distal end.

[0100] In one or more exemplary drug delivery devices, the actuator mechanism is configured to move the distal end from a principal position having a principal radial distance from the central axis of the delivery device, for example, the principal position in a first state of the drug delivery device, to a secondary position having a secondary radial distance from the central axis and / or principal axis, for example, the secondary position in a second state of the drug delivery device, in which case the secondary radial distance is greater than the principal radial distance. Therefore, when the drug delivery device is in a first state, the distal end of the mounting portion can be located at the principal position, and / or when the drug delivery device is in a second state, the distal end of the mounting portion can be located at the secondary position.

[0101] The principal radial distance may be less than 10 mm, for example less than 8 mm, or even less than 5 mm. The secondary radial distance may be greater than the principal radial distance. The secondary radial distance may be greater than 5 mm, for example greater than 6 mm or greater than 8 mm. In one or more exemplary drug delivery devices, the secondary radial distance is in the range of 6 mm to 15 mm.

[0102] In one or more exemplary drug delivery devices, attachment portions such as a needle and / or a portion of the distal end can be located, or at least partially located, within a first body recess of a first body portion in a first state. In the first state, the distal end can be located inside the first body portion.

[0103] In one or more exemplary drug delivery devices, the attachment portion, such as a needle and / or a portion of its distal end, may be positioned outside the first body recess of the first body portion in the second state, or at least partially positioned thereon.

[0104] In one or more exemplary drug delivery devices, a mounting portion, such as a needle and / or a part of its distal end, may be positioned in a second body recess of a second body portion in a first state. This mounting portion may be configured to fix the first body portion to the second body portion in the first state of the drug delivery device.

[0105] In one or more exemplary drug delivery devices, attachment portions such as a needle and / or a portion of its distal end may be positioned outside the second body portion and / or at least outside the second body recess of the second body portion in the second state.

[0106] In one or more exemplary drug delivery devices, the actuator mechanism is configured to move the distal end from a principal angular position of the principal position to a secondary angular position of the secondary position relative to the proximal end of the mounting portion (base portion) by rotation, for example, around a first rotation axis of the mounting portion. The angle between the principal angular position and the secondary angular position can be greater than 10°, for example, greater than 45° or greater than 60°.

[0107] In one or more exemplary drug delivery devices, the drug delivery device is equipped with a locking mechanism. The locking mechanism may be configured to fix the first body portion to a second body portion in a first state of the drug delivery device, for example, by preventing rotation. The locking mechanism may be configured to fix the mounting portion to the first body portion in a primary position when the drug delivery device is in a first state, for example. When the locking mechanism is released, the mounting portion may be made movable from the primary position to a secondary position. When released, the locking mechanism may be configured to allow the first body portion to rotate relative to the second body portion, for example in a second state of the drug delivery device.

[0108] The locking mechanism may comprise a first locking element optionally configured to fix and / or release (unlock) the first body portion relative to a second body portion. The first locking element may be configured to fix and / or release (unlock) a mounting portion relative to the first body portion or the second body portion. The first locking element may be positioned in a first main recess of the first body portion and / or a second main recess of the second body portion. The first locking element may be configured to dissolve when the drug delivery device enters the gastrointestinal tract or a desired position within the gastrointestinal tract, thereby releasing the first body portion relative to the second body portion, allowing the actuator mechanism to rotate the first body portion relative to the second body portion, thereby moving the distal end and consequently attaching the drug delivery device to the internal tissue.

[0109] The first locking element may be a first locking band (e.g., a ring, a loop, a partial ring, a partial loop). The first locking band may have a circumferential length greater than its longitudinal width. For example, the circumferential length may be 2, 3, 4, 5, 6, 7, 8, 9, or 10 times the longitudinal width.

[0110] The first locking band can be fitted to the outer surface of the drug delivery device. For example, the first locking band can be positioned on the outer surface of the first or second body portion. The first locking band can be mechanically fitted to the drug delivery device. For example, the first locking band can be snap-fitted to the drug delivery device. The first locking band can be chemically attached to the drug delivery device.

[0111] In one or more exemplary drug delivery devices, the first locking band may be in the shape of a capsule portion. For example, the first locking band may form the first half of a capsule. The first locking band may form the first half of a capsule, and the second locking band may form the second half of a capsule. When fitted together, the first and second locking bands may form a complete capsule.

[0112] The first locking band, if positioned on the first body, may partially or completely cover the recess of the first body. Therefore, the first locking band, if on the first body, may prevent movement of the mounting portion. The first locking band, if positioned on the second body, may partially or completely cover the recess of the second body. Therefore, the first locking band, if on the second body, may prevent movement of the mounting portion.

[0113] The first lock band may extend completely along the outer circumference of the drug delivery device. The first lock band may extend over 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of the outer circumference of the drug delivery device. The first lock band may extend beyond 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of the outer circumference of the drug delivery device. The first lock band may extend over less than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of the outer circumference of the drug delivery device.

[0114] In one or more exemplary drug delivery devices, the first lock band may comprise one or more locking protrusions (e.g., extensions, tabs, fingers, projections, teeth). For example, the first lock band may comprise one, two, three, four, five, six, seven, eight, nine, or ten locking protrusions. The locking protrusions may extend longitudinally from one side of the first lock band only. The locking protrusions may extend longitudinally from both sides of the first lock band. The locking protrusions may be arranged at equal intervals along the first lock band. The locking protrusions may be arranged at unequal intervals along the first lock band.

[0115] One or more locking protrusions may extend toward the longitudinal center of the drug delivery device (for example, toward the second body portion along the outer surface of the body if the first locking band is located on the first body portion, or toward the first body portion along the outer surface of the body if the first locking band is located on the second body portion).

[0116] One or more locking protrusions may be triangular, square, rectangular, circular, or other polygonal in shape. One or more locking protrusions may change shape along the first locking band.

[0117] In one or more exemplary drug delivery devices, the drug delivery device may have a mating configuration. The mating configuration can be configured to engage with one or more projections of a first locking band. The mating configuration may comprise one or more mating projections (e.g., extensions, tabs, fingers, projections, teeth) extending radially outward from the outer surface of the drug delivery device. The mating configuration may extend from a first body portion, a second body portion, or both. The mating configuration may be formed by one or more circumferential rows. For example, there may be one circumferential row of mating configurations, or two circumferential rows of mating configurations. Both circumferential rows may lie on the same body portion (e.g., the first body portion or the second body portion). In another embodiment, one circumferential row of mating configurations may lie on the first body portion, and a second circumferential row of mating configurations may lie on the second body portion.

[0118] One or more interlocking projections may be triangular, square, rectangular, circular, or other polygonal in shape. One or more interlocking projections may change shape along the first locking band. One or more interlocking projections may be angled circumferentially to form interlocking recesses (e.g., curves, cavities, spaces, gaps). These interlocking recesses may assist in securing one or more interlocking projections to one or more projections of the first locking band. Furthermore, the interlocking recesses may prevent undesirable release of the first locking band. Thus, when the first locking band is attached to the drug delivery device, one or more locking projections may be interlockable between one or more interlocking projections. One or more locking projections may be interlockable within adjacent interlocking projections. This may prevent rotation of the first body relative to the second body. For example, the first body is prevented from rotating by the first locking band. In some embodiments, the locking projections may be positioned between two interlocking projections, each interlocking projection being angled in opposite directions to hold the locking projection in place.

[0119] In some embodiments, the mating configuration may be a recess extending into the interior of the drug delivery device. In this case, the locking projection may extend radially inward instead of longitudinally to engage with the mating configuration.

[0120] As described above, when the first locking band is attached and one or more projections engage with the fitting configuration, the first body portion is fixed in a predetermined position relative to the second body portion. The first and second body portions may be released from the first locking band when the first locking band melts, as discussed herein.

[0121] Furthermore, the dissolution of the first locking band may allow the attachment portion to rotate further and detach from either the first or second body recess. Thus, as the first and second bodies rotate relative to each other, the attachment portion becomes rotatable for insertion into tissue.

[0122] In one or more exemplary drug delivery devices, the first locking band may comprise a plurality of square locking protrusions and a plurality of triangular locking protrusions. The square locking protrusions may be used to hold the cover in place under the force of the interlocking protrusions. The triangular locking protrusions may be used to properly install the first locking band.

[0123] In one or more exemplary drug delivery systems, the entire first lock band is dissolvable. In one or more exemplary drug delivery systems, only the square lock projection may be formed from a dissolvable material. Once the square lock projection is dissolved, the first and second body parts may become rotatable. Rotation of the first body part relative to the second body part may cause the first lock band to move, for example, by motion, repositioning, or changing location. This may occur when the interlocking projection compresses the triangular lock projection, pushing the lock projection longitudinally and releasing it. For example, rotation may cause the first lock band to move along its central axis.

[0124] This movement may expose the mounting portion. This movement may completely move the first locking band and detach it from the drug delivery device. By moving it, the first locking band may be partially moved, exposing the mounting portion while the first locking band remains associated with the drug delivery device, for example, attached.

[0125] The locking mechanism may comprise a second locking element optionally configured to fix and / or release the first body portion relative to a second body portion. The second locking element may be located in a first secondary recess of the first body portion and / or a second secondary recess of the second body portion. The second locking element may be configured to dissolve when the drug delivery device enters the gastrointestinal tract, thereby releasing or disengaging the first body portion relative to the second body portion, allowing the actuator mechanism to rotate the first body portion relative to the second body portion, thereby moving the first distal end toward the second distal end, and consequently attaching the drug delivery device to the internal tissue.

[0126] One or more exemplary drug delivery devices may comprise a first cover band (e.g., a ring, a loop, a partial ring, a partial loop). The first cover band can be used in conjunction with a first locking element, e.g., a locking element, a locking mechanism, etc. In one or more exemplary drug delivery devices, the first cover band may be a first locking band. In one or more exemplary drug delivery devices, the first cover band may comprise any or all of the forms of the first locking band discussed above. The first cover band may have a circumferential length greater than its longitudinal width. For example, the circumferential length may be 2, 3, 4, 5, 6, 7, 8, 9, or 10 times the longitudinal width.

[0127] The first cover band can be fitted onto the outer surface of the drug delivery device. For example, the first cover band can be installed on the outer surface of the first or second main body portion.

[0128] In one or more exemplary drug delivery devices, the first cover band may be in the shape of a capsule portion. For example, the first cover band may form the front half of the capsule. The first cover band can form the front half of the capsule, and the second cover band can form the back half of the capsule. When fitted together, the first and second cover bands can form a complete capsule.

[0129] The first cover band can be mechanically fitted to the drug delivery device. For example, the first cover band can be snap-fitted to the drug delivery device. The first cover band can be chemically attached to the drug delivery device.

[0130] The first cover band, if installed on the first body portion, can partially or completely cover the recess of the first body. Therefore, if installed on the first body portion, the first cover band can prevent movement of the mounting portion. If installed on the second body, the first cover band can partially or completely cover the recess of the second body. Therefore, if installed on the second body portion, the first cover band can prevent movement of the mounting portion.

[0131] The first cover band may extend completely along the outer circumference of the drug delivery device. The first cover band may extend over 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of the outer circumference of the drug delivery device. The first cover band may extend beyond 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of the outer circumference of the drug delivery device. The first cover band may extend over less than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of the outer circumference of the drug delivery device.

[0132] In one or more exemplary drug delivery devices, the first cover band may have one or more mating projections (e.g., extensions, tabs, fingers, protrusions, teeth). For example, the first cover band may have 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mating projections. The mating projections may extend longitudinally from one side of the first cover band only. The mating projections may extend longitudinally from both sides of the first cover band. The mating projections may be arranged at equal intervals along the first cover band. The mating projections may be arranged at unequal intervals along the first cover band.

[0133] One or more mating projections may extend toward the longitudinal center of the drug delivery device (for example, toward the second body portion along the outer surface of the body if the first cover band is installed on the first body portion, or toward the first body portion along the outer surface of the body if the first cover band is installed on the second body portion).

[0134] In one or more exemplary drug delivery devices, the drug delivery device may have a mating configuration. The mating configuration may be configured to engage with, for example, receive, hold, or contact one or more mating projections of a first cover band. The mating configuration may comprise one or more body mating projections (e.g., extensions, tabs, fingers, projections, teeth) extending radially outward from the outer surface of the drug delivery device. The mating configuration may extend from a first body portion, a second body portion, or both. The mating configuration can be formed in one or more circumferential rows. For example, one circumferential row of mating configurations or two circumferential rows of mating configurations may exist. Both circumferential rows may lie on the same body portion (e.g., a first body portion or a second body portion). In another embodiment, one circumferential row of the mating configuration may be located on a first body portion, and a second circumferential row of the mating configuration may be located on a second body portion.

[0135] One or more mating projections may be triangular, square, rectangular, circular, or other polygonal in shape. One or more mating projections may change shape along the first cover band. One or more mating projections may be angled in the circumferential direction to form mating recesses (e.g., curves, cavities, spaces, gaps). These mating recesses may assist in mating one or more body mating projections onto one or more projections of the first cover band. Furthermore, the mating recesses may prevent undesirable disengagement of the first cover band.

[0136] Therefore, when the first cover band is attached to the drug delivery device, one or more mating projections can be mated between one or more mating configurations. One or more mating projections can be mated within adjacent mating configurations. This can help to properly align the first cover band.

[0137] In some embodiments, the mating configuration may be a recess extending inward into the drug delivery device. In this case, the mating projection may extend radially inward instead of longitudinally to mate with the mating configuration. In one or more exemplary drug delivery devices, the cover band may be moved, e.g., repositioned, or relocated by rotation of the first body portion relative to the second body portion. For example, rotation may move the cover band along its central axis. This movement may expose the mounting portion. This may occur, for example, when a mating projection compresses a triangular mating projection or a mating projection of another shape, pushing the triangular mating projection longitudinally and releasing it. This movement may allow the cover band to be completely moved away from the drug delivery device. Movement may also allow the cover band to be partially moved while it is associated with the drug delivery device, e.g., attached, to expose the mounting portion.

[0138] In one or more exemplary drug delivery devices, the first cover band may be soluble. Dissolution of the first cover band may allow the attachment portion to rotate further and detach from one of the first or second body recesses. Thus, as the first and second bodies rotate relative to each other, the attachment portion is rotatable to insert into tissue. The material and / or properties of the first locking element and / or second locking element may be selected so as to control the release of the body portion and / or the operation of drug delivery to occur at a desired location within the gastrointestinal tract, e.g., the stomach or intestine. The material of the first locking element and / or second locking element may comprise one or more of sugars, sugar derivatives, hydrophilic polymers, pH-dependent polymers, and pharmaceutically acceptable excipients, which disperse, dissolve, swell, and / or gel upon contact with water / liquid.

[0139] In one or more exemplary drug delivery devices, at least a portion of the mounting portion may be made of a biodegradable material, absorbable material, or similar material that allows the material of the mounting portion to be destroyed, decomposed and / or dissolved by processes (processing methods) present in the human body, such as corrosion, decomposition, hydrolysis and / or decomposition by proteolytic enzymes. Thus, if the mounting portion is in the human body for a certain period of time, the mounting portion may lose its structural stability and, as a result, dissolve, disintegrate, or decompose to the extent that the mounting portion itself can sequentially release the drug delivery device from the surface to which it is attached. Thus, after a certain period, for example when a drug substance is released from the mounting portion, the mounting portion may have deteriorated to the extent that the drug delivery device can be released and continue to move through the gastrointestinal tract and be released by the user's or patient's natural bowel movements and / or defecation.

[0140] In one or more exemplary drug delivery devices, the drug delivery device may be partially biodegradable. In one or more exemplary drug delivery devices, the drug delivery device may be fully biodegradable. For example, all components of the drug delivery device may be biodegradable. Therefore, nothing needs to be excreted from the patient after swallowing the drug delivery device. In one or more exemplary drug delivery devices, the drug delivery device is biodegradable. In one or more exemplary drug delivery devices, the drug delivery device may be compostable.

[0141] For example, the first main body, the second main body, the mounting part, and the actuator mechanism can all be biodegradable. Furthermore, any connecting components between them can also be biodegradable.

[0142] In one or more exemplary drug delivery devices, the rotational axis (principal axis) of the first body portion and / or the second body portion may be the central axis of the drug delivery device. For example, the principal axis of the first body portion may be coaxial with the central axis. Thus, the central axis may cross both the first body portion and the second body portion, defining the principal axis.

[0143] In one or more exemplary drug delivery devices, the first body portion and the second body portion may be substantially symmetrical in the radial direction perpendicular to the central axis. This may mean that the first body portion and / or the second body portion may have a circular outer circumference, the outer circumference of which may extend radially away from the central axis and perpendicular to the central axis.

[0144] The first mounting axis can be considered as an axis coaxial with the length of the mounting portion. The second mounting axis can be considered as an axis coaxial with the length of the mounting portion. When the mounting portion has a shape that is not straight, the first mounting axis can be defined as an axis that crosses the distal and proximal ends of the mounting portion. The second mounting axis can also be defined as an axis that crosses the distal and proximal ends of the mounting portion.

[0145] In one or more exemplary drug delivery devices, a first mounting axis may be located at a first distance from the central axis, while a second mounting axis may be located at a second distance from the central axis and / or main axis.

[0146] For example, the first mounting axis may be located at a first principal distance from the central axis in a first state of the drug delivery device. The first principal distance may be greater than 0.5 mm, for example, in the range of 1 mm to 15 mm, or greater than 1 mm, for example, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, or 14 mm.

[0147] The first mounting axis may intersect with the central axis or approach the central axis (distance less than 0.5 mm) in the first state of the drug delivery device.

[0148] The first mounting axis may be located at a first secondary distance from the central axis in the second state of the drug delivery device. The first secondary distance may be greater than 0.5 mm, for example, in the range of 1 mm to 15 mm, or it may be greater than 1 mm, for example, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, or 14 mm.

[0149] The first mounting axis may intersect with the central axis or approach the central axis (distance less than 0.5 mm) in the second state of the drug delivery device.

[0150] For example, the second mounting axis may be located at a second principal distance from the central axis in the first state of the drug delivery device. The second principal distance can be greater than 0.5 mm, for example, in the range of 1 mm to 15 mm, or it can be greater than 1 mm, for example, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, or 14 mm.

[0151] The second mounting axis may intersect with the central axis or approach the central axis (distance less than 0.5 mm) in the first state of the drug delivery device.

[0152] The second mounting axis may be located at a second secondary distance from the central axis in the second state of the drug delivery device. The second secondary distance may be greater than 0.5 mm and, for example, in the range of 1 mm to 15 mm, or it may be greater than 1 mm and, for example, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, or 14 mm.

[0153] The second mounting axis may intersect with the central axis or approach the central axis (distance less than 0.5 mm) in the second state of the drug delivery device.

[0154] In one or more exemplary drug delivery devices, a first body portion may be configured to rotate in a first direction, and a second body portion may be configured to rotate in a second direction, where the first direction is opposite to the second direction. Thus, for example, the first body portion may rotate clockwise, while the second body portion may rotate in the opposite and counterclockwise directions. In one or more examples in which the drug delivery device comprises three or more body portions, adjacent or nearby body portions may rotate in opposite directions. This also means that body portions may rotate in the same direction every other body portion. For example, when the first and third body portions rotate in the same first direction, the second and / or fourth body portions may rotate in a second direction opposite to the first direction.

[0155] In one or more exemplary drug delivery devices, the actuator mechanism may comprise one or more elastic parts, such as a plurality of elastic parts.

[0156] In one or more exemplary drug delivery devices, a tip may be provided at the distal end of the mounting portion, configured to penetrate biological tissue. In one or more exemplary drug delivery devices, a sharp tip may be provided at the distal end of the mounting portion, configured to penetrate biological tissue. The sharp tip may be positioned near the distal end of the mounting portion, in which case the sharp tip may be configured to have a diameter at the distal end that is smaller than the diameter of the mounting portion at a distance from the distal end. When a rotational force is applied to the mounting portion, the mounting portion may be configured such that the force applied by the actuator mechanism causes the sharp tip to penetrate biological tissue.

[0157] When the attachment portion penetrates biological tissue through rotation between the first and second main body parts (movement of the distal end), the penetration point within the biological tissue can be used to deliver the drug substance from the drug delivery device to the biological tissue, in which case the drug substance can be introduced into the biological tissue, i.e., beyond the mucous membrane. As a result, the drug substance can enter the bloodstream more easily than when the drug substance is released in the gastric or intestinal lumen, and drug delivery can be made more effective. An example of this is when the drug substance is insulin, in which case insulin can be broken down in the gastrointestinal tract and is not absorbed from the gastrointestinal tract, but in this case the mucous membrane is penetrated, and insulin is released through the penetrated gastrointestinal wall, remaining intact and reaching the user's bloodstream via the blood vessels of the intestinal layer beyond the mucous membrane (surface).

[0158] In one or more exemplary drug delivery devices, the mounting portion may include a gripping portion configured to grip biological tissue. The gripping portion can be used to improve the tactile force between the mounting portion and the mucous membrane, thereby enabling the mounting portion to secure the drug delivery device within the user's body. The gripping portion may be a portion that increases mechanical friction between the mounting portion and the surface to which it is attached, in which case the gripping portion may have, for example, a hook shape so that biological tissue located near the mounting portion is gripped by the portion.

[0159] In one or more exemplary drug delivery devices, a portion of the elastic part may be connected to a first body part, and a second portion of the elastic part may be connected to a second body part. This means that the elastic part can be used to store energy, such as rotational energy or rotational force, applied to the first and second body parts, and that energy is stored in the elastic part. Furthermore, when the energy is released, for example when a locking element dissolves or decomposes, the force can be released to both the first and second body parts, which then transmit the force to the mounting part. The elastic part may be in the shape of, for example, a spiral helical spring (main spring) and / or a spiral torsion spring, in which case the first body part may be wound around the second body part by rotating the first body part relative to the second body part. This stores energy in the main spring by twisting the helical body more strongly. Next, as the main spring unwinds, the accumulated force of the main spring can rotate the first body portion in the opposite direction. Thus, the force of the main spring can move the mounting portion, in which case the mounting portion can penetrate the tissue and attach the drug delivery device to the living tissue.

[0160] When a drug delivery device enters the body, and for example, enters a desired part of the gastrointestinal tract, the drug delivery device may be configured to change from a first state to a second state. The change can be initiated by various means, in which case, for example, the first and second body parts can be held in the first state using a locking mechanism, the locking mechanism comprising one or more locking elements made of, for example, a soluble, swellable, or decomposable material, in which case the material reacts with the surroundings within the desired body part, for example, a fluid, thereby unlocking or releasing the locking mechanism. The material of the locking element may be a material that loses its structural strength when in contact with the surroundings within the desired body part. For example, the locking element(s) may be made of a polymer material or a sugary substance, the polymer material or sugary substance may dissolve, swell, or decompose when the locking element comes into contact with a certain type of liquid, which may contain enzymes or a certain type of acid within the digestive system. When the locking element comes into contact with the reagent, the material may dissolve, expand, or decompose over time, and when the rotational force of the drug delivery device exceeds the static force of the locking element, the rotational force may be released by the rotation of the first body part relative to the second body part, or vice versa.

[0161] In one or more exemplary drug delivery devices, a locking element can fix the mounting element in a position that secures the first body portion to the second portion, i.e., a position that prevents the first body portion from rotating relative to the second body. If the locking element dissolves or disintegrates, the mounting portion becomes movable to a secondary position in which the mounting portion does not secure the first body portion to the second portion, for example, an actuator mechanism rotates the mounting portion around a rotation axis relative to the body portion to which the mounting portion is rotatably mounted.

[0162] The second state of the drug delivery device may be considered to begin with the release of energy stored in the actuator mechanism, for example, one or more elastic parts of the actuator mechanism, into the rotational forces of the first and / or second body parts and / or the rotational forces of the attachment part to the first or second body part. The end of the second state may be considered to be the point at which the energy stored in the elastic parts becomes stationary again, i.e., when the attachment part grasps or penetrates biological tissue and / or when the rotational motion between the first and second body parts stops.

[0163] In one or more exemplary drug delivery devices, the drug delivery device may have a first state in which the actuator mechanism has a constant elastic load, and a second state in which the actuator mechanism releases the elastic load. In the first state, the constant elastic load can be considered as energy stored in the actuator mechanism, in which case the elastic load is greater than zero. The second state can be considered as a state in which the actuator mechanism releases its elastic load, in which case the elastic load decreases, for example, to zero, by rotating the first body part relative to the second body part. The second state may end when the mounting part comes into contact with or penetrates biological tissue, and the elastic load does not change, even if it does not reach zero. Thus, when the drug delivery device is attached to the wall of a biological material, and the elastic load becomes stationary after the release of the elastic force, a third state may follow the second state.

[0164] The attachment portion may have a deployment function, in which case, during the first state of the drug delivery device, i.e., during the initial state of the drug delivery device, the attachment portion may be positioned or placed inside the first or second main body portion, or alternatively, the attachment portion may be folded along the side of the main body portion. Another method of achieving the same can be considered. The folded state (first state) may be maintained using, for example, a releaseable locking mechanism of an encapsulation form, the encapsulation form being similar to a capsule (coating), band or plug for the drug substance, and made of, for example, gelatin, sugar or another soluble material or a material that causes it to lose its structural strength. Thus, the attachment portion may be held in place until the drug delivery device enters the gastrointestinal tract, e.g., the stomach, such that the attachment portion does not interfere with or damage the inner wall of the mouth and / or esophagus. Before or during the transition to the second state, the attachment portion may extend outward from the main body portion, so that the attachment portion can interact with the inner wall of the digestive system. When the mounting portion is folded or retracted, the distance from the central axis to the distal end of the mounting portion is longer in the second state than in the first state. Consequently, the diameter of the drug delivery device in the first state is smaller than the diameter of the drug delivery device in the second state.

[0165] In one or more exemplary drug delivery devices, at least a portion of the mounting parts, such as needles, may be made of a material comprising one or more of magnesium, titanium, iron, and zinc, which allows for precise and accurate control of the size and / or shape / geometric shape of the mounting parts, and subsequently allows the delivery device to have the desired mounting capacity and / or small manufacturing variability, which is particularly important in the pharmaceutical industry.

[0166] The attachment portion of a needle, etc., may be made of a material comprising one or more of magnesium, titanium, iron, and zinc. The material of the attachment portion / needle may be biocompatible and / or biodegradable, such as biocompatible and / or biodegradable materials. The material of the attachment portion / needle may comprise one or more biodegradable polymers such as PLA and / or POLGA. Some, some, most, substantially all, or all of the material of the attachment portion / needle may be biocompatible and / or biodegradable. The material of the attachment portion of a needle, etc., may comprise, be composed of, or be essentially composed of, biocompatible and / or biodegradable materials such as biocompatible and / or biodegradable metals. The material of the attachment portion of a needle, etc., may comprise biodegradable or bioabsorbable metals or metal alloys, such as magnesium, zinc, and / or iron, or alloys comprising one or more of magnesium, zinc, and iron. Biodegradable or bioabsorbable metals or metal alloys can be understood as metals or metal alloys that safely decompose in practical time, such as in the human body, in relation to the use of the metal or metal alloy. The material of attachment parts such as needles may comprise one or more metals, such as a combination of one or more metals, or a metal alloy.

[0167] The advantage of using biodegradable materials for the attachment portion is that, because biodegradable materials gradually decompose over time, after the delivery device is attached to an inner surface, such as the intestinal wall, the sharp properties of the attachment material allow the delivery device to deliver the active drug substance or payload, which is located in the attachment portion and / or the main body of the delivery device, to a specific part of the patient's body, such as the stomach or intestines, over a long period of time. Furthermore, if the material of the attachment portion is biodegradable, the attachment portion decomposes within the human body and disappears after delivering the payload / active drug substance contained in the drug delivery device, thereby avoiding harm to the human patient over time. The attachment portion may be configured to decompose over time intervals of, for example, 2 hours, 5 hours, 10 hours, 20 hours, or 24 hours, or over days such as 1 day, 2 days, 5 days, or over weeks such as 1 week, 2 weeks, 3 weeks, or 5 weeks.

[0168] The material of the attachment portion of a needle or the like may comprise one or more of magnesium (Mg), zinc (Zn), and / or iron (Fe), or a combination thereof. The advantage of having an attachment portion made of Mg, Zn, and / or Fe is that the shape and size of the attachment portion can be precisely controlled, thereby improving attachment to an internal surface, such as the inner wall of a human patient's intestine.

[0169] For example, the material of the attachment part of a needle or the like may consist of 0.001% to 100% by weight of biodegradable metals, such as 0.001% to 100% by weight of magnesium, 0.001% to 100% by weight of zinc, or 0.001% to 100% by weight of iron.

[0170] The material for the attachment part of the needle, etc., may comprise, for example, 0.001% by weight of Mg, 0.005% by weight of Mg, 0.01% by weight of Mg, 0.05% by weight of Mg, 0.1% by weight of Mg, 0.5% by weight of Mg, 1% by weight of Mg, 5% by weight of Mg, 10% by weight of Mg, 20% by weight of Mg, 30% by weight of Mg, 40% by weight of Mg, 50% by weight of Mg, 60% by weight of Mg, 70% by weight of Mg, 80% by weight of Mg, 90% by weight of Mg, or 100% by weight of Mg.

[0171] The material for the mounting portion of the needle, etc., may comprise, for example, 0.001% by weight of Zn, 0.005% by weight of Zn, 0.01% by weight of Zn, 0.05% by weight of Zn, 0.1% by weight of Zn, 0.5% by weight of Zn, 1% by weight of Zn, 5% by weight of Zn, 10% by weight of Zn, 20% by weight of Zn, 30% by weight of Zn, 40% by weight of Zn, 50% by weight of Zn, 60% by weight of Zn, 70% by weight of Zn, 80% by weight of Zn, 90% by weight of Zn, or 100% by weight of Zn.

[0172] The material for the mounting portion of the needle, etc., may comprise, for example, 0.001% by weight of Fe, 0.005% by weight of Fe, 0.01% by weight of Fe, 0.05% by weight of Fe, 0.1% by weight of Fe, 0.5% by weight of Fe, 1% by weight of Fe, 5% by weight of Fe, 10% by weight of Fe, 20% by weight of Fe, 30% by weight of Fe, 40% by weight of Fe, 50% by weight of Fe, 60% by weight of Fe, 70% by weight of Fe, 80% by weight of Fe, 90% by weight of Fe, or 100% by weight of Fe.

[0173] The material for the mounting portion of the needle, etc., may comprise a metal alloy such as Zn-Mg, Zn-Fe, Mg-Fe, or Zn-Mg-Fe. For example, the material for the mounting portion of the needle, etc., may comprise a Zn-Mg alloy having 0.001% by weight of Mg, 0.005% by weight of Mg, 0.01% by weight of Mg, 0.05% by weight of Mg, 0.1% by weight of Mg, 0.5% by weight of Mg, 1% by weight of Mg, 5% by weight of Mg, 10% by weight of Mg, 20% by weight of Mg, 30% by weight of Mg, 40% by weight of Mg, 50% by weight of Mg, 60% by weight of Mg, 70% by weight of Mg, 80% by weight of Mg, or 90% by weight of Mg.

[0174] The material for the mounting portion of the needle, etc., may be, for example, a Zn-Fe alloy having 0.001% by weight of Fe, 0.005% by weight of Fe, 0.01% by weight of Fe, 0.05% by weight of Fe, 0.1% by weight of Fe, 0.5% by weight of Fe, 1% by weight of Fe, 5% by weight of Fe, 10% by weight of Fe, 20% by weight of Fe, 30% by weight of Fe, 40% by weight of Fe, 50% by weight of Fe, 60% by weight of Fe, 70% by weight of Fe, 80% by weight of Fe, or 90% by weight of Fe.

[0175] The material for the mounting portion of the needle, etc., may comprise, for example, an Mg-Fe alloy containing 0.001% by weight of Fe, 0.005% by weight of Fe, 0.01% by weight of Fe, 0.05% by weight of Fe, 0.1% by weight of Fe, 0.5% by weight of Fe, 1% by weight of Fe, 5% by weight of Fe, 10% by weight of Fe, 20% by weight of Fe, 30% by weight of Fe, 40% by weight of Fe, 50% by weight of Fe, 60% by weight of Fe, 70% by weight of Fe, 80% by weight of Fe, or 90% by weight of Fe.

[0176] The material for the attachment part of the needle, etc., is, for example, 0.001 wt% Fe, 0.005 wt% Fe, 0.01 wt% Fe, 0.05 wt% Fe, 0.1 wt% Fe, 0.5 wt% Fe, 1 wt% Fe, 5 wt% Fe, 10 wt% Fe, 20 wt% Fe, 30 wt% Fe, 40 wt% Fe, 50 wt% Fe, 60 wt% Fe, 70 wt% Fe, 80 wt% Fe, 90 wt% Fe, 0.001 wt% Mg, 0.005 wt% Mg, 0.01 wt% Mg, 0.05 wt% Mg, 0.1 wt% Mg, 0.5 wt% Mg, 1 wt% Mg, 5 wt% Mg, 10 wt% The Zn-Mg-Fe alloy may contain % Mg, 20% Mg by weight, 30% Mg by weight, 40% Mg by weight, 50% Mg by weight, 60% Mg by weight, 70% Mg by weight, 80% Mg by weight, 90% Mg by weight, 0.001% Zn by weight, 0.005% Zn by weight, 0.01% Zn by weight, 0.05% Zn by weight, 0.1% Zn by weight, 0.5% Zn by weight, 1% Zn by weight, 5% Zn by weight, 10% Zn by weight, 20% Zn by weight, 30% Zn by weight, 40% Zn by weight, 50% Zn by weight, 60% Zn by weight, 70% Zn by weight, 80% Zn by weight, or 90% Zn by weight.

[0177] The attachment portion of the needle or the like may be made of a material comprising one or more thermoplastic or thermosetting polymers. The material of the attachment portion of the needle or the like may comprise one or more active pharmaceutical substances. Therefore, the active pharmaceutical substances can be embedded in the material of the attachment portion of the needle or the like to form a pharmaceutical composition.

[0178] In some embodiments, the attachment portion of a needle or the like may comprise a material that is, for example, water-soluble, water-insoluble, biodegradable, non-biodegradable, and / or pH-dependent soluble. In some embodiments, the attachment portion of a needle or the like may comprise a water-soluble, biodegradable, and / or pH-dependent material, and since the material can dissolve and / or decompose, the attachment portion of a needle or the like, which is fixed in the intestinal tissue, can gradually decompose and / or dissolve. In some embodiments, the attachment portion of a needle or the like may comprise a water-soluble material that allows for immediate or controlled release of the active drug substance, depending on the selected material. In some embodiments, water-insoluble or biodegradable materials may allow the active drug substance to be stored in the attachment portion of a needle or the like for a longer release period (e.g., several days, several weeks, or several months). In some embodiments, a pH-dependent soluble material allows the attachment portion of a needle or the like to remain intact under physiological pH conditions, e.g., about 7.4, and remain intact in the gastrointestinal lumen, but can then dissolve once it enters the wall of the gastrointestinal tract. In some embodiments, one or more water-soluble, water-insoluble, biodegradable, and / or pH-dependent materials can be optionally combined to control the release of the active drug substance over a controlled release period (e.g., minutes, hours, days, weeks, or months) by diffusion or disintegration of attachment parts such as needles.

[0179] In some embodiments, attachment portions such as needles may be made from different compositions. For example, the outer portion of the attachment portion may be made from one composition, and the inner core of the attachment portion may be made from another composition. In some embodiments, the outer portion and inner core of the attachment portion may be made from, for example, water-soluble, water-insoluble, biodegradable, and / or pH-dependent materials. In some embodiments, one or more water-soluble, water-insoluble, biodegradable, and / or pH-dependent materials may be combined to control the release of active drug substances once the attachment portion can move from its position from the lumen to the internal tissue, for example, from the gastrointestinal lumen to the gastrointestinal tissue.

[0180] In some embodiments, the attachment portion, such as a needle, can be tubular and comprise a tubular body, the tubular body can comprise an active drug substance, for example, a liquid payload comprising the active drug substance optionally connected to the tubular attachment portion, so that the payload having the active drug substance can flow through the attachment portion, such as a needle, into internal tissue, for example, intestinal tissue. In some embodiments, the tubular body may contain an expanding substance, such as an expanding excipient, which, by chemical reaction, for example, when mixed, expands in volume and / or generates gas to facilitate payload delivery. In some embodiments, the expansion is by osmosis.

[0181] In some embodiments, the first compartment (a compartment for holding the active drug substance) may include a closing portion for closing the first compartment. The closing portion may contribute to improved control of the release of the active drug substance. In some embodiments, the closing portion may be composed of, for example, a water-soluble, water-insoluble, biodegradable, and / or pH-dependent material. In some embodiments, one or more water-soluble, water-insoluble, biodegradable, and / or pH-dependent materials may combine to control the release of the active drug substance from the first compartment once the attachment portion, such as a needle, moves from the lumen to the internal tissue, for example, from the gastrointestinal lumen to the gastrointestinal tissue.

[0182] Figure 1 shows an exploded view of a drug delivery device 2 according to the present disclosure, which comprises a first body portion 4 having a first end 6 and a second end 8, and a second body portion 10 having a first end 12 and a second end 14. When assembled, the first body portion 4 is rotatably connected to the second body portion 10, and when connected, the first end 6 of the first body portion abuts against the first end 12 of the second body portion.

[0183] The drug delivery device 2 further comprises an actuator mechanism 16, which in this example comprises an elastic portion 16A in the form of a helical torsion spring. The first portion 18 of the elastic portion 16A (the first end of the helical torsion spring) is located on the outer circumference 22 of the helical torsion spring, and the second portion 20 of the elastic portion 16A (the second end of the helical torsion spring) is located on the central portion 24 of the helical torsion spring.

[0184] The first body portion 4 comprises an internal volume 26, which is adapted to receive an elastic portion 16A. The inner surface 28 of the internal volume 26 comprises one or more first engaging portions 30 configured to engage with a first portion 18 of the elastic portion 16A, the first engaging portions being able to maintain the position of the first portion during rotational motion of the first body portion 4 and the second body portion 10 relative to each other. The second portion 20 of the elastic portion 16A is configured to engage with a second engaging portion located centrally inside the second body portion 10. The second engaging portion is configured to extend into the central portion 24 of the spring when the spring is placed in the internal volume 26 of the first body portion 4. The second engaging portion has a slit or groove adapted to engage with the second portion 20 of the elastic portion 16A, so that the rotational motion of the first body portion 4 and / or the second body portion 10 can wind up the elastic portion 16A when the first portion 18 engages with the first engaging portion 30.

[0185] The drug delivery device 2 has a central axis A that extends in a direction from the second end 8 of the first body portion 4 (the first end of the drug delivery device) toward the second end 14 of the second body portion (the second end of the drug delivery device). The central axis A can be considered to define the principal axis around which the first body portion 4 and the second body portion 10 rotate.

[0186] The first engaging portion 30 and the first portion 18 of the elastic portion 16A may have an engagement such that when the spring load exceeds a predetermined level, the first end releases the first engaging portion 30 and jumps into and engages with the next engaging portion 30'. This means that the drug delivery device may have a torque limiter, which ensures that the energy stored inside the elastic member 16 cannot exceed a predetermined limit.

[0187] The drug delivery device 2 comprises a mounting portion 36 having a proximal end 38 and a distal end 40. The mounting portion 36 is equipped with a straight needle 37 (or spike) and is mounted to be fixed to the first body portion 4. The mounting portion 36 extends from the outer surface 42 of the first body portion 4 toward the first mounting axis. The distal end 40 of the mounting portion 36 may have a sharp tip to allow penetration of biological tissue, where a rotational force provided by the elastic member 16A may be used to penetrate the tissue.

[0188] The distal end 40 of the attachment portion 36 can have a sharp tip, which can be similar to the sharp tip of a subcutaneous injection needle, and which can penetrate body tissue such as the mucous membrane of the intestines, stomach, internal organs, or other parts of the digestive system and / or gastrointestinal system. The needle 37 can be hollow with an opening at its distal end 40, so that after the attachment portion 36 has penetrated the living tissue, the active drug substance can be introduced into the body tissue through the opening.

[0189] The elastic force of the elastic portion 16A is used to rotate the first body portion in a first direction B and the second body portion in a second direction C, around the central axis A, which is the principal axis. In other words, the actuator mechanism 16 (elastic portion 16A) is configured to move the first distal end 40 toward the second distal end 48.

[0190] The first main body portion 4 has a first main recess 64 on its outer surface 42, and the second main body portion 10 has a second main recess 66 on its outer surface 50. The first main recess 64 and the second main recess 66 are part of a locking mechanism for fixing, for example, by arranging a first locking element in the first main recess 64 and the second main recess 66, to prevent the first main body portion 4 from rotating relative to the second main body portion 10 when the drug delivery device 2 is in a first state.

[0191] Figure 2A shows the drug delivery device 2 in a first state. The drug delivery device is equipped with a locking mechanism, indicated by a dotted ellipse 70, which comprises a first main recess 64, a second main recess 66, and a first locking element 72 positioned within the first and second main recesses 64 and 66. The first locking element 72 can prevent rotational movement of the first and second main recesses 4 and 10 relative to each other in order to maintain a stationary relationship between the main recesses 4 and 10. The first locking element 72 may be in the form of a biodegradable material, such as a sugary substance, which decomposes upon contact with gastrointestinal fluids. When the rotational force applied to the main body portions 4 and 10 via the elastic member 16A exceeds the static force of the (disassembled) first locking element 72, the first locking element 72 releases the main body portions 4 and 10, allowing the elastic member to release the stored energy, thereby causing the first main body portion 4 to rotate relative to the second main body portion 10 in the second state of the drug delivery device.

[0192] Figure 2B shows the drug delivery device 2 in which the first locking element 72 disassembles or dissolves, and the first body portion 4 and the second body portion 10 rotate relative to each other in directions B and C (respectively). Accordingly, the mounting member 36 rotates via the rotational force (torque) applied to the body portion 4 in order to penetrate the tissue via the needle 37, etc.

[0193] Figure 3 shows an exemplary pharmaceutical composition 100 comprising a drug delivery device 2, in which the drug delivery device 2 is enclosed within a housing 76 made of optionally soluble material. The pharmaceutical composition 100 comprises an active drug substance arranged in a first compartment and / or a second compartment. The housing 76 surrounds the drug delivery device 2 and may make it easier to swallow the drug delivery device 2. The soluble housing 76 can dissolve in the gastrointestinal tract, in which case the drug delivery device 2 cannot engage or attach before the housing 76 dissolves. This type of housing is known in the art in the form of a drug capsule, and the material of the drug capsule may be, for example, gelatin similar to the capsule shells of hard drugs (toxic hallucinogens) known in the art. In one or more exemplary pharmaceutical compositions, the drug delivery device may have its surface covered with a coating.

[0194] Figure 4 shows an exploded view of an exemplary drug delivery device according to the present disclosure. The drug delivery device 2A comprises a first body portion 4 having a central axis A and comprising a first main body portion 4A and a first secondary body portion 4B, and comprising two parts. The first body portion 4 may comprise a cylindrical first base portion 39.

[0195] The drug delivery device 2A comprises a second body portion 10 comprising a second main body portion 10A and a second secondary body portion 10B, and having two parts. The drug delivery device 2A also comprises a mounting portion 36 comprising a base portion 36A and a needle 37 attached to the base portion 36A. The mounting portion 36 has a distal end portion 40 and is optionally rotatably attached to the second body portion 10 via a second joint connection formed by a cylindrical second base portion 41 and a corresponding cylindrical cavity within the second body portion 10, the second joint having a second axis of rotation X_R_2. Thus, the mounting portion 36 is configured to rotate around a first axis of rotation relative to the second body portion 4. The second axis of rotation X_R_2 is parallel to the central axis A.

[0196] The drug delivery device 2A comprises a frame portion 78 formed as a shaft member or rod, to which different parts such as the first main body portion 4 and / or the second main body portion 10 are attached, for example, fixed or rotatably attached.

[0197] The drug delivery device 2A includes an actuator mechanism 16 having an elastic part 16A configured to move the mounting part 36, specifically the distal end 40 of the mounting part, by rotating the first main body part 4 relative to the second main body part 10.

[0198] Figure 5A shows an exemplary drug delivery device 2B, and Figure 5B shows an exploded version of the exemplary drug delivery device 2B. With respect to Figures 1 to 4, the drug delivery device 2B may comprise any and / or all of the configurations discussed above, unless otherwise noted.

[0199] As shown in the figure, the drug delivery device 2B may be equipped with a first body recess 108 configured to allow rotation of the mounting portion 104. The mounting portion 104 may be equipped with a joint 116, thereby forming a curved needle or spike. This allows for easier penetration into tissue.

[0200] Furthermore, as shown in the figure, the drug delivery system 2B may be equipped with a first locking band 102. The first locking band 102 can prevent the first body portion 4 from rotating relative to the second body portion 10. The first locking band 102 can be used in place of the locking element 72. Separately, the first locking band 102 can act as a first cover band 103 and can be used together with the locking element 72. Specifically, the first locking band 102 may be equipped with a plurality of locking protrusions 112. The locking protrusions 112 can be fitted into the fitting form 114 of the drug delivery device 2B. Once fitted, the locking protrusions 112 prevent the rotation of the first body portion 4 and the second body portion 10. Subsequently, the first locking band 112 may dissolve to allow rotation.

[0201] Figures 6A to 6C show diagrams of the drug delivery device 2C. Unless otherwise specified, the drug delivery device 2C may comprise any and / or all of the configurations discussed above with respect to Figures 1 to 5B.

[0202] As shown in the figure, the drug delivery device 2C may comprise a central axis A, a first body portion 4, and a second body portion 10. The drug delivery device 2C may further comprise a mounting portion 36 attached to the first body portion 4 and having a distal end. The mounting portion 36 may comprise a base portion 36A and a needle (or spike) 37. The mounting portion 36 may be rotatable within the first body recess 108. The distal end 40 (needle 37, etc.) of the mounting portion 36 has a tip configured to penetrate biological tissue.

[0203] The drug delivery device 2C may comprise a first compartment, and the drug delivery device 2C is configured to deliver an active drug substance from the first compartment to the area surrounding the drug delivery device 2C. For example, once the mounting portion 36 penetrates the tissue, the drug delivery device 2C can release the active drug substance into the tissue.

[0204] The drug delivery device 2C may also include an actuator mechanism (which may include the elastic part 16A described above, but is not limited to the central axis A) configured to rotate the first body portion 4 relative to the second body portion 10 about the principal axis of the drug delivery device 2C. As shown, the drug delivery device 2C includes only a single mounting portion 36. The actuator mechanism may include an elastic part configured to apply force to the first body portion 4 and / or the second body portion 10. The first body portion 4 is configured to rotate in a first direction, and the second body portion 10 is configured to rotate in a second direction opposite to the first direction.

[0205] The drug delivery device 2C can have a first state in which the first body portion 4 and the second body portion 10 are rotationally stationary relative to each other, and a second state in which the first body portion 4 and the second body portion 10 are rotationally movable relative to each other. Accordingly, the actuator mechanism can be configured to move the distal end 40 from a principal position having a principal radial distance from the central axis A of the drug delivery device 2C to a secondary position having a secondary radial distance from the central axis A, in which case the secondary radial distance is greater than the principal radial distance.

[0206] Therefore, when the first body portion 4 rotates relative to the second body portion 10, the mounting portion 36 can rotate and exit the first body recess 108 in order to penetrate the tissue. The mounting portion 36 can be rotatably attached to the first body portion 4 via a hinge such as a base 36A and can be configured to rotate around a first axis of rotation perpendicular or parallel to the main axis A.

[0207] Furthermore, as shown in the figure, the drug delivery device 2C may be equipped with a locking mechanism 70 comprising a first locking element 72 that holds the first body portion 4 so as to prevent rotation of the second body portion 10. The locking mechanism 70 may be configured to fix the first body portion 4 to the second body portion 10 in a first state of the drug delivery device 2C.

[0208] Optionally, the first body portion 4 and / or the second body portion 10 may be equipped with a resistance configuration 118. As shown in the figure, the resistance configuration 118 is positioned on the second body portion 10. The resistance configuration 118 may be selected from one or more of the following: a high-friction surface; a configuration configured to alter inertia; and a configuration configured to create turbulence.

[0209] The second body portion 10 may have higher inertia than the first body portion 4. The second body portion 10 may have a greater or lesser weight than the first body portion 4. This can improve, for example, the penetration of the mounting portion 36 into the tissue.

[0210] The drug delivery devices 2, 2A, 2B, and 2C may be biodegradable, such as being completely biodegradable.

[0211] Furthermore, delivery devices, methods, and compositions relating to any of the following items are also disclosed.

[0212] Item 1. A drug delivery device having a central axis, the drug delivery device is The first main body section, The second main body section, A mounting portion attached to the first main body and having a distal end, It comprises an actuator mechanism configured to rotate the first main body portion relative to the second main body portion around the main axis of the drug delivery device, The drug delivery device comprises only a single mounting portion.

[0213] Item 2. A drug delivery device according to item 1, wherein the first body portion and / or the second body portion are equipped with a resistive configuration.

[0214] Item 3. The drug delivery device according to item 2, wherein the resistance configuration is selected from one or more of the following: a high-friction surface; a configuration configured to change inertia; and a configuration configured to generate turbulence.

[0215] Item 4. A drug delivery device according to any one of items 1 to 3, wherein the second main body has higher inertia than the first main body.

[0216] Item 5. A drug delivery device according to any one of items 1 to 4, wherein the second main body is heavier or lighter in weight than the first main body.

[0217] Item 6. A drug delivery device according to any one of items 1 to 5, wherein the actuator mechanism comprises an elastic portion configured to apply force to a first body portion and / or a second body portion.

[0218] Item 7. A drug delivery device according to any one of items 1 to 6, wherein a first body portion is configured to rotate in a first direction, and a second body portion is configured to rotate in a second direction opposite to the first direction.

[0219] Item 8. A drug delivery device according to any one of items 1 to 7, comprising a tip whose distal end of the mounting portion is configured to penetrate biological tissue.

[0220] Item 9. A drug delivery device according to any one of items 1 to 8, wherein the drug delivery device comprises a first compartment and is configured to deliver an active drug substance from the first compartment to the periphery of the drug delivery device.

[0221] Item 10. A drug delivery device according to any one of items 1 to 9, having a first state in which a first body portion and a second body portion are rotationally stationary relative to each other, and a second state in which the first body portion and the second body portion are rotationally movable relative to each other.

[0222] Item 11. A drug delivery device according to any one of items 1 to 10, wherein the actuator mechanism is configured to move the distal end from a principal position having a principal radial distance from the central axis of the delivery device to a secondary position having a secondary radial distance from the central axis, and in this case, the secondary radial distance is greater than the principal radial distance.

[0223] Item 12. A drug delivery device according to any one of items 1 to 11, comprising a locking mechanism configured to fix the first body portion to the second body portion in a first state of the drug delivery device.

[0224] Item 13. A drug delivery device according to any one of items 1 to 12, wherein the mounting portion is rotatably attached to a first body portion via a hinge and configured to rotate around a first axis of rotation perpendicular to or parallel to the main axis.

[0225] Item 14. A drug delivery device described in any of items 1 to 13, wherein the drug delivery device is biodegradable.

[0226] The use of terms such as "first," "second," "third," "fourth," "primary," "secondary," and "tertiary" does not imply any particular order, but is provided to identify individual elements. Furthermore, the use of terms such as "first," "second," "third," "fourth," "primary," "secondary," and "tertiary" does not indicate any order or importance; rather, the use of terms such as "first," "second," "third," "fourth," "primary," "secondary," and "tertiary" is used to distinguish one element from another. Note that terms such as "first," "second," "third," "fourth," "primary," "secondary," and "tertiary" are used here and elsewhere solely for labeling purposes and are not intended to indicate any particular spatial or temporal ordering.

[0227] Furthermore, labeling the first element does not imply the existence of the second element, and vice versa.

[0228] It should be noted that the word "equipped with" does not necessarily exclude the existence of other elements or procedures other than those listed.

[0229] It should be noted that the word "a" (one) or "an" (one) preceding an element does not exclude the possibility of multiple such elements existing.

[0230] Furthermore, it should be noted that no reference numerals limit the scope of the claims, that exemplary embodiments may be performed at least partially by both hardware and software means, and that some “means,” “units,” or “devices” may be represented by the same hardware items.

[0231] Although the form has been illustrated and described, it is understood that the form is not intended to limit the invention described in the claims, and it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the invention described in the claims. Therefore, the specification and drawings should be considered illustrative, not restrictive. The invention described in the claims is intended to encompass all substitutes, modifications, and equivalents. [Explanation of Symbols]

[0232] 2. Drug delivery device 2A Drug delivery device 2B Drug delivery device 2C Drug delivery device 4. First main body 4A First main body section 4B First secondary body section 6. First end of the first main body 8. Second end of the first main body 10. Second main body 10A Second main body section 10B Second secondary main body section 12 First end of the second main body 14 The second end of the second main body 16 Actuator mechanism 16A Elastic part 18 First part of the elastic section 20 Second part of the elastic portion 22 Outer circumference of a spiral torsion spring 24. Central part of a spiral torsion spring 26 Internal volume 28. Inner self 30 First engagement portion 30' First engagement portion 36 Mounting part 36A base 37 needles 38 Proximal end of the mounting portion 40 Distal end of the mounting portion 42 Outer surface of the first main body 50 Outer surface of the second main body 64 First main recess of the first main body portion 66 Second main recess of the second main body portion 70 Locking mechanism 72 The first rock element 76 Housing 100 Pharmaceutical Compositions 102 The first rock band 103 The first cover band 104 Mounting part 108 First body recess 112 Locking protrusion 114 Fitting configuration 116 joints 118 Resistance form A Center axis / principal axis B Rotation direction C Rotation direction

Claims

1. A drug delivery device having a central axis, wherein this drug delivery device is The first main body part, The second main body section, A mounting portion attached to the first main body portion and having a distal end, The drug delivery device comprises an actuator mechanism configured to rotate the first main body portion relative to the second main body portion around the main axis of the drug delivery device, A drug delivery device comprising only a single mounting portion.

2. The drug delivery device according to claim 1, wherein the first main body portion and / or the second main body portion are equipped with a resistive configuration.

3. The drug delivery device according to claim 2, wherein the resistance configuration is selected from one or more of the following: a high-friction surface, a configuration configured to change inertia, and a configuration configured to generate turbulence.

4. The drug delivery device according to any one of claims 1 to 3, wherein the second main body portion has higher inertia than the first main body portion.

5. The drug delivery device according to any one of claims 1 to 4, wherein the second main body portion has a weight that is heavier or lighter than the first main body portion.

6. The drug delivery device according to any one of claims 1 to 5, wherein the actuator mechanism comprises an elastic portion configured to apply force to the first main body portion and / or the second main body portion.

7. The drug delivery device according to any one of claims 1 to 6, wherein the first main body portion is configured to rotate in a first direction, and the second main body portion is configured to rotate in a second direction opposite to the first direction.

8. The drug delivery device according to any one of claims 1 to 7, wherein the distal end of the mounting portion is configured to penetrate biological tissue, and the device further comprises a tip.

9. A drug delivery device according to any one of claims 1 to 8, wherein the drug delivery device comprises a first compartment, and the drug delivery device is configured to deliver an active drug substance from the first compartment to the surrounding area of ​​the drug delivery device.

10. The drug delivery device according to any one of claims 1 to 9, having a first state in which the first main body portion and the second main body portion are rotationally stationary relative to each other, and a second state in which the first main body portion and the second main body portion are rotationally movable relative to each other.

11. The actuator mechanism is configured to move the distal end from a principal position having a principal radial distance from the central axis of the drug delivery device to a secondary position having a secondary radial distance from the central axis. The drug delivery device according to any one of claims 1 to 10, wherein the secondary radial distance is greater than the principal radial distance.

12. The drug delivery device according to any one of claims 1 to 11, comprising a locking mechanism configured to fix the first main body portion to the second main body portion in a first state of the drug delivery device.

13. The drug delivery device according to any one of claims 1 to 12, wherein the mounting portion is rotatably attached to the first main body portion via a hinge, and is further configured to rotate around a first axis of rotation perpendicular to or parallel to the main axis.

14. A drug delivery device according to any one of claims 1 to 13, wherein the drug delivery device is biodegradable.